


HEALTHCARE

Innovations in Cancer

Novel therapeutics, new diagnostics and future R&D strategies

By Dr John Bates

 [Table of Contents](#)

Dr John Bates

Dr John Bates is an experienced director and life science consultant. After a first degree in biochemistry and chemistry (1978) and a Ph.D. in cancer research in 1981 (Aston University), John joined Upjohn Ltd, managing a team of biopharmaceutical scientists, later taking a similar role with Glaxo. In 1989 he co-founded Melbourn Scientific Ltd, establishing the company's technical and commercial capabilities, winning contracts with major pharma corporates and co-managing MSL's growth, before being bought out in 1994. He founded Pharmaceutical Technology Ltd in 1994, where he invented and developed VectaSEP CLE, sold under exclusive license to Whatman plc in 1997. In 2000 John joined ANGLE Technology Ltd, providing management and due diligence on new life science company formation in the UK and US, later joining Acumen Bioscience Ltd (drug discovery instrumentation) as Technical Director. John formed VennBio in 2002 and has provided Board level management and consultancy to life science companies (Non-exec director of Cizzle Biotechnology Ltd - lung cancer, Non-exec director of Pro-Cure Therapeutics – prostate cancer, interim CEO of MembraSense Ltd – bi-lipid biomembranes), investors (London Seed Capital), university challenge fund managers (White Rose), university enterprise departments (BRDL, CUE, Nottingham, NorBio, UEA and others) and regional life science organisations (Connect Midlands, ERBI).

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Innovations in Cancer

Executive Summary	8	
Current market landscape and dynamics	8	
Drivers and resistors of innovation	9	
Innovations in cancer therapeutics	10	
Innovations in cancer diagnostics	11	
New R&D strategies in cancer	12	
The future of the cancer market and conclusions	13	
Chapter 1	Current market landscape and dynamics	16
Summary		16
Introduction		17
Cancer epidemiology		18
Sales by drug class		20
Sales by brand		21
Sales by company		22
Sales by country		23
Gold standard treatments		24
Lung cancer		25
Colorectal cancer		25
Breast cancer		26
Ovarian		26
Uterine		27
Leukemia		27
Prostate		28
Pancreatic		28
Lymphomas		29
Unmet need		29
Innovation in the cancer market		31
Targeted therapy		32

Cancer diagnostics		33
Chapter 2	Drivers and resistors of innovation	36
Summary		36
Introduction		37
Drivers of innovation		37
Cancer statistics		38
Need		41
Risk		43
Scientific advances		43
Diagnostics		44
Resistors		45
Market fragmentation		45
Reimbursement		48
Chapter 3	Innovations in cancer therapeutics	52
Summary		52
Introduction		53
Key trends		53
Key innovations		54
Targeted therapies		54
Cancer vaccines		56
Small interfering RNAs		57
Pipeline		58
Addressing unmet need		62
Chapter 4	Innovations in cancer diagnostics	66
Summary		66
Introduction		67
Cancer biomarkers		69
Predicting cancer		70

Diagnostic innovations by indication	72
Lung	74
Colon & rectum	75
Breast	76
Ovary	78
Uterus and cervix	78
Leukemia	79
Prostate	79
Pancreas	80
Lymphomas	80
Chapter 5	New R&D strategies in cancer
	84
Summary	84
Introduction	85
Background	85
Oncogenomics	85
Scientific approaches	87
Small interfering RNA	88
Biologicals	90
Gene expression and biomarkers	91
Arrays	92
Drug delivery	93
Cancer stem cells	93
Looking ahead	94
Chapter 6	The future of the cancer market and conclusions
	98
Summary	98
Introduction	99
Key trends	100
The future	101
Chapter 7	Appendix
	104
Index	104

List of Figures

Figure 1.1:	Incidence per cancer indication and country, 2005	19
Figure 2.2:	Drivers and resistors of innovation in the cancer market	37
Figure 3.3:	Companies developing new therapeutics for the “top four” cancers, 2007	59
Figure 3.4:	Numbers of drugs in development for the “top four” cancers, 2006	60
Figure 3.5:	Top companies developing therapeutics for the “top four” cancers, 2006	61
Figure 3.6:	Phase I-III pipeline for the “top four” cancers, 2006	62
Figure 4.7:	Categorization of cancer diagnostic tests	68
Figure 4.8:	Overview of diagnostics for 10 leading cancers, 2006	73

List of Tables

Table 1.1:	Incidence of 9 major tumor types in the 7 major markets, 2005	18
Table 1.2:	Global cancer market sales by drug class, 2004-05	20
Table 1.3:	Top 20 global cancer brands, 2004-05	21
Table 1.4:	Top 20 cancer companies by global sales, 2004-05	23
Table 1.5:	Global cancer market sales by drug class, 2004-05	24
Table 1.6:	Gold standard treatments and limitations	24
Table 2.7:	The World Cancer Report – 5 year survival rates	38
Table 2.8:	Incidence and prevalence for 9 cancers in 2005, for 7 major markets (US, Japan, France, Germany, Italy, Spain, UK)	39
Table 2.9:	Pipeline cancer drugs by indication, 2006	40
Table 2.10:	Data indicating unmet need in cancers based on the numbers of patients globally, 2002	41
Table 3.11:	Cancer vaccine pipeline, 2006	56
Table 3.12:	siRNA drug pipeline, 2006	58